Search

Your search keyword '"Liu, Wen-Chun"' showing total 723 results
Start Over Author "Liu, Wen-Chun"
723 results on '"Liu, Wen-Chun"'

6. Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV

Author

Liu, Wang-Da, Lin, Meng-Shuan, Sun, Hsin-Yun, Shih, Ming-Chieh, Chuang, Yu-Chung, Huang, Yu-Shan, Lin, Kuan-Yin, Li, Guei-Chi, Wu, Pei-Ying, Chen, Ling-Ya, Liu, Wen-Chun, Su, Yi-Ching, He, Pu-Chi, Chen, Yi-Ting, Lin, Chia-Yi, Cheng, Yu-Chen, Yao, Yi, Yeh, Yi-Chen, Liu, Chia-Chi, Pan, Mei-Yan, Luo, Yu-Zhen, Chang, Hsi-Yen, Wang, Jann-Tay, Sheng, Wang-Huei, Hsieh, Szu-Min, Chang, Sui-Yuan, and Hung, Chien-Ching

Published
2024
Full Text
View/download PDF

8. Author Correction: Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

Author

Riva, Laura, Yuan, Shuofeng, Yin, Xin, Martin-Sancho, Laura, Matsunaga, Naoko, Pache, Lars, Burgstaller-Muehlbacher, Sebastian, De Jesus, Paul D., Teriete, Peter, Hull, Mitchell V., Chang, Max W., Chan, Jasper Fuk-Woo, Cao, Jianli, Poon, Vincent Kwok-Man, Herbert, Kristina M., Cheng, Kuoyuan, Nguyen, Tu-Trinh H., Rubanov, Andrey, Pu, Yuan, Nguyen, Courtney, Choi, Angela, Rathnasinghe, Raveen, Schotsaert, Michael, Miorin, Lisa, Dejosez, Marion, Zwaka, Thomas P., Sit, Ko-Yung, Martinez-Sobrido, Luis, Liu, Wen-Chun, White, Kris M., Chapman, Mackenzie E., Lendy, Emma K., Glynne, Richard J., Albrecht, Randy, Ruppin, Eytan, Mesecar, Andrew D., Johnson, Jeffrey R., Benner, Christopher, Sun, Ren, Schultz, Peter G., Su, Andrew I., García-Sastre, Adolfo, Chatterjee, Arnab K., Yuen, Kwok-Yung, and Chanda, Sumit K.

Published
2024
Full Text
View/download PDF

11. TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation

Author

Ho, Jessica Sook Yuin, Mok, Bobo Wing-Yee, Campisi, Laura, Jordan, Tristan, Yildiz, Soner, Parameswaran, Sreeja, Wayman, Joseph A, Gaudreault, Natasha N, Meekins, David A, Indran, Sabarish V, Morozov, Igor, Trujillo, Jessie D, Fstkchyan, Yesai S, Rathnasinghe, Raveen, Zhu, Zeyu, Zheng, Simin, Zhao, Nan, White, Kris, Ray-Jones, Helen, Malysheva, Valeriya, Thiecke, Michiel J, Lau, Siu-Ying, Liu, Honglian, Zhang, Anna Junxia, Lee, Andrew Chak-Yiu, Liu, Wen-Chun, Jangra, Sonia, Escalera, Alba, Aydillo, Teresa, Melo, Betsaida Salom, Guccione, Ernesto, Sebra, Robert, Shum, Elaine, Bakker, Jan, Kaufman, David A, Moreira, Andre L, Carossino, Mariano, Balasuriya, Udeni BR, Byun, Minji, Albrecht, Randy A, Schotsaert, Michael, Garcia-Sastre, Adolfo, Chanda, Sumit K, Miraldi, Emily R, Jeyasekharan, Anand D, TenOever, Benjamin R, Spivakov, Mikhail, Weirauch, Matthew T, Heinz, Sven, Chen, Honglin, Benner, Christopher, Richt, Juergen A, and Marazzi, Ivan

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Infectious Diseases, Emerging Infectious Diseases, Biodefense, Coronaviruses Therapeutics and Interventions, Lung, Coronaviruses, 5.1 Pharmaceuticals, Good Health and Well Being, Animals, COVID-19, Chlorocebus aethiops, DNA Topoisomerases, Type I, Humans, Inflammation, Mesocricetus, Mice, Mice, Transgenic, SARS-CoV-2, THP-1 Cells, Topoisomerase I Inhibitors, Topotecan, Vero Cells, COVID-19 Drug Treatment, chromatin, cytokine storm, epigenetics, inducible genes, inflammation, topoisomerase, topotecan, transcription, Biological Sciences, Medical and Health Sciences, Developmental Biology, Biological sciences, Biomedical and clinical sciences
Abstract

The ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently affecting millions of lives worldwide. Large retrospective studies indicate that an elevated level of inflammatory cytokines and pro-inflammatory factors are associated with both increased disease severity and mortality. Here, using multidimensional epigenetic, transcriptional, in vitro, and in vivo analyses, we report that topoisomerase 1 (TOP1) inhibition suppresses lethal inflammation induced by SARS-CoV-2. Therapeutic treatment with two doses of topotecan (TPT), an FDA-approved TOP1 inhibitor, suppresses infection-induced inflammation in hamsters. TPT treatment as late as 4 days post-infection reduces morbidity and rescues mortality in a transgenic mouse model. These results support the potential of TOP1 inhibition as an effective host-directed therapy against severe SARS-CoV-2 infection. TPT and its derivatives are inexpensive clinical-grade inhibitors available in most countries. Clinical trials are needed to evaluate the efficacy of repurposing TOP1 inhibitors for severe coronavirus disease 2019 (COVID-19) in humans.

Published
2021

14. Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants

Author

Sun, Cheng-Pu, Chiu, Chi-Wen, Wu, Ping-Yi, Tsung, Szu-I, Lee, I-Jung, Hu, Chih-Wei, Hsu, Min-Feng, Kuo, Tzu-Jiun, Lan, Yu-Hua, Chen, Li-Yao, Ng, Hui-Yee, Chung, Meng-Jhe, Liao, Hsin-Ni, Tseng, Sheng-Che, Lo, Chia-Hui, Chen, Yung-Jiun, Liao, Chun-Che, Chang, Chih-Shin, Liang, Jian-Jong, Draczkowski, Piotr, Puri, Sarita, Chang, Yuan-Chih, Huang, Jing-Siou, Chen, Cheng-Cheung, Kau, Jyh-Hwa, Chen, Yen-Hui, Liu, Wen-Chun, Wu, Han-Chung, Danny Hsu, Shang-Te, Wang, I-Hsuan, and Tao, Mi-Hua

Published
2023
Full Text
View/download PDF

17. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

Author

Riva, Laura, Yuan, Shuofeng, Yin, Xin, Martin-Sancho, Laura, Matsunaga, Naoko, Pache, Lars, Burgstaller-Muehlbacher, Sebastian, De Jesus, Paul D, Teriete, Peter, Hull, Mitchell V, Chang, Max W, Chan, Jasper Fuk-Woo, Cao, Jianli, Poon, Vincent Kwok-Man, Herbert, Kristina M, Cheng, Kuoyuan, Nguyen, Tu-Trinh H, Rubanov, Andrey, Pu, Yuan, Nguyen, Courtney, Choi, Angela, Rathnasinghe, Raveen, Schotsaert, Michael, Miorin, Lisa, Dejosez, Marion, Zwaka, Thomas P, Sit, Ko-Yung, Martinez-Sobrido, Luis, Liu, Wen-Chun, White, Kris M, Chapman, Mackenzie E, Lendy, Emma K, Glynne, Richard J, Albrecht, Randy, Ruppin, Eytan, Mesecar, Andrew D, Johnson, Jeffrey R, Benner, Christopher, Sun, Ren, Schultz, Peter G, Su, Andrew I, García-Sastre, Adolfo, Chatterjee, Arnab K, Yuen, Kwok-Yung, and Chanda, Sumit K

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Infectious Diseases, Lung, Pneumonia & Influenza, Orphan Drug, Emerging Infectious Diseases, Coronaviruses Therapeutics and Interventions, Pneumonia, Coronaviruses, Rare Diseases, Stem Cell Research, 5.1 Pharmaceuticals, Infection, Good Health and Well Being, Adenosine Monophosphate, Alanine, Alveolar Epithelial Cells, Antiviral Agents, Betacoronavirus, COVID-19, Cell Line, Coronavirus Infections, Cysteine Proteinase Inhibitors, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Drug Repositioning, Drug Synergism, Gene Expression Regulation, Humans, Hydrazones, Induced Pluripotent Stem Cells, Models, Biological, Morpholines, Pandemics, Pneumonia, Viral, Pyrimidines, Reproducibility of Results, SARS-CoV-2, Small Molecule Libraries, Triazines, Virus Internalization, Virus Replication, COVID-19 Drug Treatment, General Science & Technology
Abstract

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 has triggered an ongoing global pandemic of the severe pneumonia-like disease coronavirus disease 2019 (COVID-19)1. The development of a vaccine is likely to take at least 12-18 months, and the typical timeline for approval of a new antiviral therapeutic agent can exceed 10 years. Thus, repurposing of known drugs could substantially accelerate the deployment of new therapies for COVID-19. Here we profiled a library of drugs encompassing approximately 12,000 clinical-stage or Food and Drug Administration (FDA)-approved small molecules to identify candidate therapeutic drugs for COVID-19. We report the identification of 100 molecules that inhibit viral replication of SARS-CoV-2, including 21 drugs that exhibit dose-response relationships. Of these, thirteen were found to harbour effective concentrations commensurate with probable achievable therapeutic doses in patients, including the PIKfyve kinase inhibitor apilimod2-4 and the cysteine protease inhibitors MDL-28170, Z LVG CHN2, VBY-825 and ONO 5334. Notably, MDL-28170, ONO 5334 and apilimod were found to antagonize viral replication in human pneumocyte-like cells derived from induced pluripotent stem cells, and apilimod also demonstrated antiviral efficacy in a primary human lung explant model. Since most of the molecules identified in this study have already advanced into the clinic, their known pharmacological and human safety profiles will enable accelerated preclinical and clinical evaluation of these drugs for the treatment of COVID-19.

Published
2020

21. Viral Determinants in H5N1 Influenza A Virus Enable Productive Infection of HeLa Cells.

Author

Rodriguez-Frandsen, Ariel, Martin-Sancho, Laura, Gounder, Anshu, Chang, Max, Liu, Wen-Chun, De Jesus, Paul, von Recum-Knepper, Jessica, Dutra, Miriam, Huffmaster, Nicholas, Chavarria, Monica, Mena, Ignacio, Riva, Laura, Nguyen, Courtney, Dobariya, Saunil, Herbert, Kristina, Benner, Christopher, Albrecht, Randy, García-Sastre, Adolfo, and Chanda, Sumit

Subjects
H5N1, HeLa, heterokaryon, highly pathogenic, influenza A virus, A549 Cells, Animals, Birds, Cell Line, Dogs, HEK293 Cells, HeLa Cells, Humans, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza A Virus, H5N1 Subtype, Influenza A virus, Influenza in Birds, Influenza, Human, Madin Darby Canine Kidney Cells, Viral Tropism, Virus Replication
Abstract

Influenza A virus (IAV) is a human respiratory pathogen that causes yearly global epidemics, as well as sporadic pandemics due to human adaptation of pathogenic strains. Efficient replication of IAV in different species is, in part, dictated by its ability to exploit the genetic environment of the host cell. To investigate IAV tropism in human cells, we evaluated the replication of IAV strains in a diverse subset of epithelial cell lines. HeLa cells were refractory to the growth of human H1N1 and H3N2 viruses and low-pathogenic avian influenza (LPAI) viruses. Interestingly, a human isolate of the highly pathogenic avian influenza (HPAI) H5N1 virus successfully propagated in HeLa cells to levels comparable to those in a human lung cell line. Heterokaryon cells generated by fusion of HeLa and permissive cells supported H1N1 virus growth, suggesting the absence of a host factor(s) required for the replication of H1N1, but not H5N1, viruses in HeLa cells. The absence of this factor(s) was mapped to reduced nuclear import, replication, and translation, as well as deficient viral budding. Using reassortant H1N1:H5N1 viruses, we found that the combined introduction of nucleoprotein (NP) and hemagglutinin (HA) from an H5N1 virus was necessary and sufficient to enable H1N1 virus growth. Overall, this study suggests that the absence of one or more cellular factors in HeLa cells results in abortive replication of H1N1, H3N2, and LPAI viruses, which can be circumvented upon the introduction of H5N1 virus NP and HA. Further understanding of the molecular basis of this restriction will provide important insights into the virus-host interactions that underlie IAV pathogenesis and tropism.IMPORTANCE Many zoonotic avian influenza A viruses have successfully crossed the species barrier and caused mild to life-threatening disease in humans. While human-to-human transmission is limited, there is a risk that these zoonotic viruses may acquire adaptive mutations enabling them to propagate efficiently and cause devastating human pandemics. Therefore, it is important to identify viral determinants that provide these viruses with a replicative advantage in human cells. Here, we tested the growth of influenza A virus in a subset of human cell lines and found that abortive replication of H1N1 viruses in HeLa cells can be circumvented upon the introduction of H5N1 virus HA and NP. Overall, this work leverages the genetic diversity of multiple human cell lines to highlight viral determinants that could contribute to H5N1 virus pathogenesis and tropism.

Published
2020

22. Evolution of anti-SARS-CoV-2 spike protein titers after two-dose of COVID-19 vaccination among people living with HIV

Author

Liu, Wang-Da, Pang, Man Wai, Wang, Jann-Tay, Sun, Hsin-Yun, Huang, Yu-Shan, Lin, Kuan-Yin, Wu, Un-In, Li, Guei-Chi, Liu, Wen-Chun, Su, Yi-Ching, He, Pu-Chi, Lin, Chia-Yi, Yeh, Chih-Yu, Cheng, Yu-Chen, Yao, Yi, Chen, Yi-Ting, Wu, Pei-Ying, Chen, Ling-Ya, Luo, Yu-Zhen, Chang, Hsi-Yen, Sheng, Wang-Huei, Hsieh, Szu-Min, Chang, Sui-Yuan, Hung, Chien-Ching, and Chang, Shan-Chwen

Published
2022
Full Text
View/download PDF

24. Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens

Author

Chen, Guan-Jhou, Sun, Hsin-Yun, Chen, Ling-Ya, Hsieh, Szu-Min, Sheng, Wang-Hui, Liu, Wang-Da, Chuang, Yu-Chung, Huang, Yu-Shan, Lin, Kuan-Yin, Wu, Pei-Ying, Chang, Hsi-Yen, Luo, Yu-Zhen, Su, Yi-Ching, Liu, Wen-Chun, Chang, Sui-Fang, Chang, Sui-Yuan, and Hung, Chien-Ching

Published
2022
Full Text
View/download PDF

26. The Efficacy of Omega-3 Fatty Acids as the Monotherapy for Depression: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.

Author

Wu, Suet-Kei, Yang, Kai-Jie, Liu, Wen-Chun, Malau, Ikbal Andrian, Zailani, Halliru, Chang, Cheng-Ho, Huang, Shih-Yi, Chang, Jane Pei-Chen, Chiu, Wei-Che, and Su, Kuan-Pin

Abstract

Objective: Omega-3 polyunsaturated fatty acids (n-3 PUFAs) have demonstrated protective effects in major depressive disorder (MDD) patients receiving antidepressant treatment. However, there have been a few double-blind randomized controlled trials focused on n-3 PUFAs as monotherapy in MDD, and the outcomes have been mixed. This study aimed to assess the clinical effects of n-3 PUFAs monotherapy in patients with MDD. Methods: A total of 60 patients with MDD participated in this 12-week double-blind randomized controlled trial. They were randomized to either the n-3 PUFAs group (n = 30; 3.2 g of eicosapentaenoic acid, EPA and docosahexaenoic acid, DHA per day) or the placebo group (n = 30; 3.2 g of soybean oil per day). The severity of depression was evaluated using the Hamilton Rating Scale for Depression (HRSD). Results: The n-3 PUFAs group had a significantly lower HRSD score compared with the placebo group at week 4 (p = 0.004), week 6 (p = 0.006), week 8 (p = 0.004), and week 12 (p = 0.01). The n-3 PUFAs group showed slightly higher rates for both remission (26.7% vs. 10%, p = 0.095) and response (23.3% vs. 6.7%, p = 0.145) compared with the placebo group at week 12, but these differences did not reach statistical significance. Conclusions: These findings suggested that monotherapy of n-3 PUFAs could improve depression and potentially serve as an alternative option for MDD patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants

Author

Lee, I-Jung, Sun, Cheng-Pu, Wu, Ping-Yi, Lan, Yu-Hua, Wang, I-Hsuan, Liu, Wen-Chun, Yuan, Joyce Pei-Yi, Chang, Yu-Wei, Tseng, Sheng-Che, Tsung, Szu-I, Chou, Yu-Chi, Kumari, Monika, Lin, Yin-Shiou, Chen, Hui-Feng, Chen, Tsung-Yen, Lin, Chih-Chao, Chiu, Chi-Wen, Hsieh, Chung-Hsuan, Chuang, Cheng-Ying, Cheng, Chao-Min, Lin, Hsiu-Ting, Chen, Wan-Yu, Hsu, Fu-Fei, Hong, Ming-Hsiang, Liao, Chun-Che, Chang, Chih-Shin, Liang, Jian-Jong, Ma, Hsiu-Hua, Chiang, Ming-Tsai, Liao, Hsin-Ni, Ko, Hui-Ying, Chen, Liang-Yu, Ko, Yi-An, Yu, Pei-Yu, Yang, Tzu-Jing, Chiang, Po-Cheng, Hsu, Shang-Te, Lin, Yi-Ling, Lee, Chong-Chou, Wu, Han-Chung, and Tao, Mi-Hua

Published
2022
Full Text
View/download PDF

34. Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience

Author

Bryce, Clare, Grimes, Zachary, Pujadas, Elisabet, Ahuja, Sadhna, Beasley, Mary Beth, Albrecht, Randy, Hernandez, Tahyna, Stock, Aryeh, Zhao, Zhen, AlRasheed, Mohamed Rizwan, Chen, Joyce, Li, Li, Wang, Diane, Corben, Adriana, Haines, G. Kenneth, III, Westra, William H., Umphlett, Melissa, Gordon, Ronald E., Reidy, Jason, Petersen, Bruce, Salem, Fadi, Fiel, Maria Isabel, El Jamal, Siraj M., Tsankova, Nadejda M., Houldsworth, Jane, Mussa, Zarmeen, Veremis, Brandon, Sordillo, Emilia, Gitman, Melissa R., Nowak, Michael, Brody, Rachel, Harpaz, Noam, Merad, Miriam, Gnjatic, Sacha, Liu, Wen-Chun, Schotsaert, Michael, Miorin, Lisa, Aydillo Gomez, Teresa A., Ramos-Lopez, Irene, Garcia-Sastre, Adolfo, Donnelly, Ryan, Seigler, Patricia, Keys, Calvin, Cameron, Jennifer, Moultrie, Isaiah, Washington, Kae-Lynn, Treatman, Jacquelyn, Sebra, Robert, Jhang, Jeffrey, Firpo, Adolfo, Lednicky, John, Paniz-Mondolfi, Alberto, Cordon-Cardo, Carlos, and Fowkes, Mary E.

Published
2021
Full Text
View/download PDF

35. Tissue-based SARS-CoV-2 detection in fatal COVID-19 infections: Sustained direct viral-induced damage is not necessary to drive disease progression

Author

El Jamal, Siraj M., Pujadas, Elisabet, Ramos, Irene, Bryce, Clare, Grimes, Zachary M., Amanat, Fatima, Tsankova, Nadejda M., Mussa, Zarmeen, Olson, Sara, Salem, Fadi, Miorin, Lisa, Aydillo, Teresa, Schotsaert, Michael, Albrecht, Randy A., Liu, Wen-Chun, Marjanovic, Nada, Francoeur, Nancy, Sebra, Robert, Sealfon, Stuart C., García-Sastre, Adolfo, Fowkes, Mary, Cordon-Cardo, Carlos, and Westra, William H.

Published
2021
Full Text
View/download PDF

37. A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics

Author

Si, Longlong, Bai, Haiqing, Rodas, Melissa, Cao, Wuji, Oh, Crystal Yuri, Jiang, Amanda, Moller, Rasmus, Hoagland, Daisy, Oishi, Kohei, Horiuchi, Shu, Uhl, Skyler, Blanco-Melo, Daniel, Albrecht, Randy A., Liu, Wen-Chun, Jordan, Tristan, Nilsson-Payant, Benjamin E., Golynker, Ilona, Frere, Justin, Logue, James, Haupt, Robert, McGrath, Marisa, Weston, Stuart, Zhang, Tian, Plebani, Roberto, Soong, Mercy, Nurani, Atiq, Kim, Seong Min, Zhu, Danni Y., Benam, Kambez H., Goyal, Girija, Gilpin, Sarah E., Prantil-Baun, Rachelle, Gygi, Steven P., Powers, Rani K., Carlson, Kenneth E., Frieman, Matthew, tenOever, Benjamin R., and Ingber, Donald E.

Published
2021
Full Text
View/download PDF

39. Prognostic Evaluation of Conversion Therapy following Hepatic Arterial Infusion Chemotherapy or Immunotherapy in Patients with Advanced or Transarterial Chemoembolization Unsuitable Intermediate-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study.

Author

Kuo, Li-Fu, Liu, Wen-Chun, Li, Ming-Feng, Huang, Fu-Huan, Chou, Chu-Kuang, Chen, Tsung-Hsien, Tsai, Yi-Tseng, Hsu, Ping-I., Li, Chao-Jen, Wu, I.-Ting, and Tsai, Kun-Feng

Subjects
*CONVERSION therapy, *IMMUNE checkpoint inhibitors, *OVERALL survival, *PROGNOSIS, *SURVIVAL rate, *CHEMOEMBOLIZATION
Abstract

Introduction: Patients with advanced-stage or intermediate-stage hepatocellular carcinoma (HCC) unsuitable for transarterial chemoembolization (TACE) had poor prognoses. Recent advancements in hepatic arterial infusion chemotherapy (HAIC) and immune checkpoint inhibitors (ICIs) have demonstrated higher tumor response rates, which improved overall survival (OS). HAIC achieves an OS rate of approximately 14.5–15.3 months with a 39.1–42.5% tumor response rate. In comparison, ICIs have a 12–14 month OS rate with a 26–33% tumor response rate. Given these promising responses, this study evaluates the efficacy of conversion therapy with curative intent following HAIC or ICIs, focusing on survival outcomes. Methods: We retrospectively analyzed 80 patients with advanced or TACE-unsuitable intermediate HCC. Patients completed two HAIC or four ICI cycles, followed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria imaging. Based on demographics, cirrhosis status, Barcelona Clinic Liver Cancer classification (BCLC) stage, treatment responses, and treatment modality, survival impacts were analyzed. OS was compared between HAIC and immunotherapy groups. The effect of conversion therapy with curative intent on survival outcomes was analyzed using a Cox regression model. Results: Among the 80 patients, 26 achieved positive response (CR/PR) with HAIC or ICIs, and 9 of them subsequently underwent conversion therapy with curative intent. Key prognostic factors included Child-Pugh stage B versus A (HR = 2.21, p = 0.041), BCLC stage C versus B (HR = 4.38, p = 0.011), and elevated alpha-fetoprotein levels (HR = 5.02, p < 0.001). Positive responders saw substantial survival benefits (HR = 0.26, p = 0.001). Patients undergoing conversion therapy exhibited significantly enhanced survival. Median OS was 13.58 months with standard therapy, while the curative intent surgery group did not reach the median OS (p = 0.002). For CR/PR patients, 48-month survival was 75.0% for the curative surgery group versus 38.0% for standard treatment. Conclusion: Conversion therapy with curative intent following HAIC or ICIs might enhance survival in patients with advanced or TACE-unsuitable intermediate-stage HCC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Animal models for COVID-19

Author

Muñoz-Fontela, César, Dowling, William E., Funnell, Simon G. P., Gsell, Pierre-S., Riveros-Balta, A. Ximena, Albrecht, Randy A., Andersen, Hanne, Baric, Ralph S., Carroll, Miles W., Cavaleri, Marco, Qin, Chuan, Crozier, Ian, Dallmeier, Kai, de Waal, Leon, de Wit, Emmie, Delang, Leen, Dohm, Erik, Duprex, W. Paul, Falzarano, Darryl, Finch, Courtney L., Frieman, Matthew B., Graham, Barney S., Gralinski, Lisa E., Guilfoyle, Kate, Haagmans, Bart L., Hamilton, Geraldine A., Hartman, Amy L., Herfst, Sander, Kaptein, Suzanne J. F., Klimstra, William B., Knezevic, Ivana, Krause, Philip R., Kuhn, Jens H., Le Grand, Roger, Lewis, Mark G., Liu, Wen-Chun, Maisonnasse, Pauline, McElroy, Anita K., Munster, Vincent, Oreshkova, Nadia, Rasmussen, Angela L., Rocha-Pereira, Joana, Rockx, Barry, Rodríguez, Estefanía, Rogers, Thomas F., Salguero, Francisco J., Schotsaert, Michael, Stittelaar, Koert J., Thibaut, Hendrik Jan, Tseng, Chien-Te, Vergara-Alert, Júlia, Beer, Martin, Brasel, Trevor, Chan, Jasper F. W., García-Sastre, Adolfo, Neyts, Johan, Perlman, Stanley, Reed, Douglas S., Richt, Juergen A., Roy, Chad J., Segalés, Joaquim, Vasan, Seshadri S., Henao-Restrepo, Ana María, and Barouch, Dan H.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results